YM BIOSCIENCES
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
YM BIOSCIENCES
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
1994-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.ymbiosciences.com
Total Employee:
11+
Status:
Closed
Contact:
(905) 629-9761
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Zoom Video Conferencing Zoom Proofpoint NetNames DNS
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Leadiant Biosciences
Leadiant Biosciences is a pharmaceutical company dedicated to the development, registration and commercialization of effective therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-10-06 | Cytopia | Cytopia acquired by YM BioSciences | N/A |
| 2006-04-01 | Eximias Pharmaceutical Corporation | Eximias Pharmaceutical Corporation acquired by YM BioSciences | 29 M USD |
Official Site Inspections
http://www.ymbiosciences.com
- Host name: 64-79-124-206.static.wiline.com
- IP address: 64.79.124.206
- Location: Belmont United States
- Latitude: 37.5136
- Longitude: -122.2916
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94002
More informations about "YM BioSciences"
YM BioSciences - Crunchbase Company Profile & Funding
Organization. YM BioSciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. YM BioSciences is a life sciences …See details»
YM Biosciences - Wikipedia
YM BioSciences' principal medicine of interest was a monoclonal antibody – Nimotuzumab – targeting the epidermal growth factor receptor. YM BioSciences received Orphan Drug Designation from the FDA for Nimotuzumab in 2004 and received a number of single-patient IND clearances starting in 2005. After receiving approval from the Office of Foreign Asset Control in March 200, the first patient was treated at Doernbecher Children's Hospital of Oregon Health an…See details»
YM Biosciences - PitchBook
YM Biosciences General Information Description. Developer of life sciences products. The company licenses and commercializes drug products and technologies primarily for the …See details»
YM BioSciences - Ownership and Business Overview - Mergr
Dec 12, 2012 YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which …See details»
YM BioSciences - Funding, Financials, Valuation & Investors
Organization. YM BioSciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Funding. YM BioSciences is registered …See details»
Company YM BioSciences Inc. - MarketScreener.com
YM BioSciences Inc.: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Toronto S.E.: YM ...See details»
YM BioSciences Inc. - Mississauga, Canada - bionity.com
Aug 12, 2010 YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide.See details»
YM BioSciences - Tech Stack, Apps, Patents & Trademarks
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-relatedSee details»
YM BioSciences - Products, Competitors, Financials, Employees ...
YM BioSciences is a life sciences product development company advancing a diverse portfolio of hematology and cancer-related products at various stages of development. In February 2013, …See details»
Cuban Life Sciences YM BioSciences Inc - cresswelladvisors.com
YM BioSciences was incorporated in 1994 as one of Canada's first "receptor companies" designed to advance the novel biotechnological basic research from academic institutes …See details»
YM BioSciences USA - PitchBook
Oct 4, 2000 YM BioSciences USA General Information Description. Developer of products for the treatment of cancer, cancer-related disorders and infectious diseases. The company's …See details»
YM BioSciences - Company Profile - Tracxn
Oct 20, 2024 YM BioSciences was focussed on developing cancer-related drugs. Its lead candidate CYT387, which it got from the acquisition of Cytopia was a JAK inhibitor which was …See details»
Top 10 Synthetic Biology Companies - genengnews.com
Jul 2, 2021 Investors pumped $4.6 billion into synthetic biology or “synbio” companies—more than four times the $904.7 million invested in the sector during Q1 2020, according to figures …See details»
YM BioSciences Inc. Stock - MarketScreener.com
YM BioSciences Inc. (YM.TSX ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock YM BioSciences Inc. | Toronto S.E.: YM | Toronto S.E.See details»
Successful completion of the seed funding round for Ymmunobio!
Nov 10, 2023 Basel, Switzerland & Princeton, NJ, USA, November 10, 2023 ─ Ymmunobio, a global preclinical stage oncology biotech company focused on the development of innovative …See details»
YM BioSciences completes merger with Cytopia - bionity.com
CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 by Dr. Andrew Wilks, the founder of Cytopia. A Phase I/II myelofibrosis study commenced in …See details»
Y-mAbs Therapeutics, Inc. | Home
Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical, global biopharmaceutical company that is focused on the research and development of innovative …See details»
Oligonucleotide - YMC America
Oligonucleotides are the forefront of new (mRNA) vaccines and therapies that hold great promise for the future of the medical world. YMC has been at the side of peptide and oligo scientists for …See details»
Biosynthesis Systems - YMC America
Biosynthesis systems are integral to our customers in the fast-growing field of therapeutic compounds such as peptides and oligonucleotides. Biosynthesis systems build, through a …See details»
北京茂扬生物技术有限公司
Apr 18, 2010 北京茂扬生物技术有限公司成立于2009年，是一家以生物技术外包服务为主营业务的民营科技企业。作为国内领先的专业化服务公司，主要为国内外新药研究和基础研究两大领 …See details»